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Pulmonary vein thromboses (PVTs) are believed to be rare; how-
ever, using 64-slice multidetector CT (64-MDCT), I have reported a
number of cases of PVT in elderly patients with chest pains since 2012
[1–10]. In 2014, I reported that 61% (35 patients) of 57 elderly patients
with chest pain had PVTs [5], which suggests that PVTs are common in
elderly patients with chest pain. PVTs can release microclots that can
occlude the microarteries of all organs, which inhibits the supply of
oxygen and nutrients by inhibiting the arterial ﬂow. Such conditions
can cause and promote heart failure and activate nuclear respiratory
factor-1 (NRF-1; CGCRTGCGCR), metal responsive transcription factor-of possible function of ncRNA (1019
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152 H. Takeuchi / IJC Heart & Vasculature 7 (2015) 151–1521 (MTF-1; TGCRCNC) and hypoxia inducible factors (HIFs; RCGTG).
These transcription factors and c-Myc (CACGTG) might bind and co-
function on CGCGTGCGCACGTG sequences, which are termed NMHs.
SLC5A7 (a choline transporter) is known to be associated with heart
rate variability. SLC5A7 has an NMH that is 481 Kb from the ATG start
codon that contains the sequence TGTGTGTGTGTGTGT GTGTGCGCGC
ACACG (termed FRONT1) before the NMH. A 29-nt FRONT1 is included
in the ncRNA (LOC 101927056), and a 30-nt FRONT1 is included in the
near regions of genes such as FZD7 (cardiac differentiation), SERPINE2,
FAM124B, OR2A2, LAMP3, CSMD1, SOX-11 and GRM1. Additionally,
FRONT1 is highly conserved in Sjogren syndrome antigen B (SSB),
which is associated with cardiovascular disease, PDIA6, PPARA (acute
myocardial infarction), PDE3A (cardiac remodeling), CRIM1 (chronic
heart failure), AFF2, SOX2-OT and PAX4 (transcriptional modulator)
(Fig. 1). Some of these genes are associated with cardiovascular
disease.
Initially, FRONT1 + NMH might be activated, and ncRNA might
subsequently be activated by FRONT1. The FRONT1 of LOC 101927056
has no NMH at all. Finally, ncRNA might activate many other genes,
and these genes might form a network that changes the characteristics
of to survive under new hypoxic and undernourished conditions.
Cardiovascular agents cannot reach the pathologic parts of the heart
through occluded microvessels. I have reported some PVT cases in
which warfarin [1] and dabigatran [3–5,10] dissolved the PVTs. War-
farin and dabigatran might ameliorate cardiovascular disease by
increasing microarterial blood ﬂow. FRONT1 might be useful as a
novel prognostic factor and a new target for the development of drugs
for cardiovascular disease. Microclots released from PVTsmight occlude
small coronary arteries and cause slow ﬂow syndrome of the coronary
arteries. To clarify these relationships, additional studies are needed. It
is important to use 64-MDCT to demonstrate PVTs when we estimate
the effects of anticoagulants on PVTs.Conﬂict of interest
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